156 related articles for article (PubMed ID: 35059568)
1. In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy.
Cui CS; Kumar V; Gorman DM; Clark RJ; Lee JD; Woodruff TM
ACS Pharmacol Transl Sci; 2022 Jan; 5(1):41-51. PubMed ID: 35059568
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice.
Kumar V; Lee JD; Clark RJ; Noakes PG; Taylor SM; Woodruff TM
ACS Omega; 2020 Feb; 5(5):2345-2354. PubMed ID: 32064396
[TBL] [Abstract][Full Text] [Related]
3. A novel anticonvulsant mechanism via inhibition of complement receptor C5ar1 in murine epilepsy models.
Benson MJ; Thomas NK; Talwar S; Hodson MP; Lynch JW; Woodruff TM; Borges K
Neurobiol Dis; 2015 Apr; 76():87-97. PubMed ID: 25681535
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function.
Li XX; Lee JD; Massey NL; Guan C; Robertson AAB; Clark RJ; Woodruff TM
Biochem Pharmacol; 2020 Oct; 180():114156. PubMed ID: 32682759
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice.
Kumar V; Lee JD; Clark RJ; Woodruff TM
Sci Rep; 2018 May; 8(1):8101. PubMed ID: 29802264
[TBL] [Abstract][Full Text] [Related]
6. The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1.
Shutov LP; Warwick CA; Shi X; Gnanasekaran A; Shepherd AJ; Mohapatra DP; Woodruff TM; Clark JD; Usachev YM
J Neurosci; 2016 May; 36(18):5055-70. PubMed ID: 27147658
[TBL] [Abstract][Full Text] [Related]
7. Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration.
Wu MCL; Lee JD; Ruitenberg MJ; Woodruff TM
J Immunol; 2020 Nov; 205(10):2834-2839. PubMed ID: 33028618
[TBL] [Abstract][Full Text] [Related]
8. C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta.
Hernandez MX; Namiranian P; Nguyen E; Fonseca MI; Tenner AJ
ASN Neuro; 2017 Feb; 9(1):1759091416687871. PubMed ID: 28078911
[TBL] [Abstract][Full Text] [Related]
9. Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients.
Karasu E; Demmelmaier J; Kellermann S; Holzmann K; Köhl J; Schmidt CQ; Kalbitz M; Gebhard F; Huber-Lang MS; Halbgebauer R
Front Immunol; 2020; 11():1789. PubMed ID: 32983087
[TBL] [Abstract][Full Text] [Related]
10. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity.
Gorman DM; Li XX; Lee JD; Fung JN; Cui CS; Lee HS; Rolfe BE; Woodruff TM; Clark RJ
J Med Chem; 2021 Nov; 64(22):16598-16608. PubMed ID: 34762432
[TBL] [Abstract][Full Text] [Related]
11. Complement C5a Receptor 1 Exacerbates the Pathophysiology of
Herrmann JB; Muenstermann M; Strobel L; Schubert-Unkmeir A; Woodruff TM; Gray-Owen SD; Klos A; Johswich KO
mBio; 2018 Jan; 9(1):. PubMed ID: 29362231
[TBL] [Abstract][Full Text] [Related]
12. The C5a/C5aR1 axis promotes progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia/reperfusion injury.
Peng Q; Wu W; Wu KY; Cao B; Qiang C; Li K; Sacks SH; Zhou W
Kidney Int; 2019 Jul; 96(1):117-128. PubMed ID: 31029505
[TBL] [Abstract][Full Text] [Related]
13. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin.
Sadik CD; Miyabe Y; Sezin T; Luster AD
Semin Immunol; 2018 Jun; 37():21-29. PubMed ID: 29602515
[TBL] [Abstract][Full Text] [Related]
14. C5aR1 Mediates the Progression of Inflammatory Responses in the Brain of Rats in the Early Stage after Ischemia and Reperfusion.
Shi Y; Jin Y; Li X; Chen C; Zhang Z; Liu X; Deng Y; Fan X; Wang C
ACS Chem Neurosci; 2021 Nov; 12(21):3994-4006. PubMed ID: 34637270
[TBL] [Abstract][Full Text] [Related]
15. Investigating the Dynamic Binding Behavior of PMX53 Cooperating with Allosteric Antagonist NDT9513727 to C5a Anaphylatoxin Chemotactic Receptor 1 through Gaussian Accelerated Molecular Dynamics and Free-Energy Perturbation Simulations.
Xiaoli A; Yuzhen N; Qiong Y; Yang L; Yao X; Bing Z
ACS Chem Neurosci; 2022 Dec; 13(23):3502-3511. PubMed ID: 36428153
[TBL] [Abstract][Full Text] [Related]
16. C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma.
Nabizadeh JA; Manthey HD; Panagides N; Steyn FJ; Lee JD; Li XX; Akhir FNM; Chen W; Boyle GM; Taylor SM; Woodruff TM; Rolfe BE
FASEB J; 2019 Oct; 33(10):11060-11071. PubMed ID: 31298935
[TBL] [Abstract][Full Text] [Related]
17. Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ.
Coulthard LG; Hawksworth OA; Li R; Balachandran A; Lee JD; Sepehrband F; Kurniawan N; Jeanes A; Simmons DG; Wolvetang E; Woodruff TM
J Neurosci; 2017 May; 37(22):5395-5407. PubMed ID: 28455369
[TBL] [Abstract][Full Text] [Related]
18. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.
Ting E; Guerrero AT; Cunha TM; Verri WA; Taylor SM; Woodruff TM; Cunha FQ; Ferreira SH
Br J Pharmacol; 2008 Mar; 153(5):1043-53. PubMed ID: 18084313
[TBL] [Abstract][Full Text] [Related]
19. C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from γδ-T cells.
Zheng QY; Xu F; Yang Y; Sun DD; Zhong Y; Wu S; Li GQ; Gao WW; Wang T; Xu GL; Liang SJ
FASEB J; 2020 Aug; 34(8):10590-10604. PubMed ID: 32557852
[TBL] [Abstract][Full Text] [Related]
20. Effect of a C5a receptor antagonist on macrophage function in an intestinal transplant rat model.
Toyama C; Maeda A; Kogata S; Takase K; Kodama T; Masahata K; Ueno T; Kamiyama M; Tazuke Y; Eguchi H; Matsunami K; Miyagawa S; Okuyama H
Transpl Immunol; 2022 Jun; 72():101559. PubMed ID: 35227893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
